Helius Medical Technologies — is a neurotechnology company best known for its PoNS® (Portable Neuromodulation Stimulator) device, which helps patients with balance and gait impairments caused by brain injuries, stroke, or multiple sclerosis. In 2025, the company went beyond traditional medtech and introduced the Solana Treasury strategy, starting to acquire SOL tokens and shaping a new digital development vector. This combination of medicine, neuroscience, and blockchain solutions makes Helius an interesting player at the intersection of healthcare and decentralized finance.
Additionally, it is important to note that Helius combines an academic research base with entrepreneurial flexibility. The company does not limit itself to scientific publications but actively brings developments to the market. This makes it attractive not only to doctors and patients but also to investors seeking long-term projects with growth potential.
- Company and the PoNS® Key Technology
- Clinical Effectiveness and Helius Medical Technologies Research
- Regulatory Achievements and Market Applications
- Solana Treasury and Blockchain Initiatives
- Opportunities, Risks, and the Future
Company and the PoNS® Key Technology
Helius Medical Technologies, Inc. (ticker HSDT, NASDAQ) focuses on developing solutions to restore functions in patients with neurological deficits. The company’s flagship product is PoNS®. This small device delivers electrical stimulation to the tongue, activating neural pathways associated with the trigeminal and facial nerves. Such stimulation improves brain neuroplasticity and helps patients regain balance and coordination.
PoNS is used only in combination with rehabilitation exercises, which ensures long-term results. An important advantage of the device is that it does not require surgery. Essentially, it is a portable neurostimulator designed for widespread use in both clinical and home settings.
Additionally, the company positions PoNS as a tool that can be integrated into existing rehabilitation programs without radical changes. This increases the chances of widespread adoption in medical centers. The device is also actively used in collaborations with universities and private clinics, accelerating the accumulation of clinical data. In the long term, PoNS could become the standard therapy for entire categories of patients.
Clinical Effectiveness and Helius Medical Technologies Research
The company has conducted extensive research to confirm the effectiveness of PoNS. In one project, carried out with Pacific Blue Cross and HealthTech Connex, patients with chronic brain injuries participated. The results were impressive:
-
67% showed clinically significant improvement in balance and gait.
-
56% were able to return to their previous jobs within six months after therapy.
-
89% noted that balance problems no longer prevented employment.
Helius also launched a number of specialized programs:
-
PoNSTEP — observation of patients with multiple sclerosis.
-
Trials with patients after chronic-stage stroke.
-
Real-world cases assessing fall risk in people with TBI, MS, and stroke.
These studies show that PoNS does not simply provide temporary relief but significantly improves the quality of life for patients who found traditional therapy insufficient.
Importantly, the company focuses on long-term monitoring of patient outcomes. In many cases, positive effects are maintained even months after therapy ends. This provides grounds to discuss the formation of lasting changes in the nervous system. In addition, the accumulated data contributes to building knowledge bases that can be used to refine treatment algorithms.
Regulatory Achievements and Market Applications
For any medical technology, regulatory approval is a key success factor. Licensing and authorization determine how quickly a device can reach the market and become available to patients. In the case of Helius Medical Technologies, the company consistently expands the list of countries where PoNS is officially recognized and works on new indications to broaden patient coverage. Below are the main achievements and current status by region:
| Region / Authority | Approval Status | Main Indications |
|---|---|---|
| USA (FDA) | Marketing authorization granted | Gait deficit in patients with multiple sclerosis (mild to moderate) |
| Canada | Approved | Gait impairment after stroke, balance after TBI, MS |
| Europe | Under research | Planned indication expansion |
| USA (trials) | Ongoing | Stroke, TBI, fall risk |
Expanding regulatory status is crucial: it determines device availability and potential market growth. Given millions of patients with neurological impairments worldwide, demand for such solutions could be enormous.
Regulatory victories also strengthen the company’s position in the eyes of investors. Having FDA and Health Canada approvals is a significant competitive advantage. In addition, this opens the door to partnerships with international pharmaceutical companies and insurance systems. With the right strategy, Helius can secure a niche as a global player in rehabilitation technologies.
Solana Treasury and Blockchain Initiatives
In addition to medical research, Helius actively seeks new directions for growth and business diversification. In recent years, the company has turned to blockchain opportunities, considering it not only as a tool for capital storage but also as a potential platform for integrating medical solutions. This step allows Helius to position itself at the intersection of traditional healthcare and the digital economy, attracting attention from both biomedical investors and the crypto market. Key steps include:
-
Closing a deal with Pantera Capital and Summer Capital worth over $500 million.
-
Starting acquisition of SOL tokens to form a corporate treasury.
-
Positioning blockchain assets as part of a long-term strategy.
-
Potential applications: managing medical data, transparent patient registries, reward systems.
So far, no official announcements have been made about integrating PoNS with blockchain platforms. However, the very fact of investment in Solana indicates the company’s desire to become part of the digital economy and attract Web3 investors.
Such a strategy can create a synergy effect: the medical brand gains access to a new audience, while the crypto industry acquires a real-sector player. This strengthens trust in projects based on Solana. Moreover, the company demonstrates readiness for diversification and adoption of new financial instruments. All this allows Helius to be seen as an example of bold adaptation to future trends.
Opportunities, Risks, and the Future
Helius stands at the crossroads of medicine and digital assets. On the one hand, PoNS has already proven its clinical effectiveness, receiving approvals in the USA and Canada. On the other hand, the SOL financial strategy makes the company more visible in the world of Web3.
Opportunities: expansion of FDA indications, international growth, blockchain integration for medical data management.
Risks: high cryptocurrency volatility, complex regulatory barriers to combining medicine and blockchain, and the need for large-scale clinical studies.
The company’s future will depend on whether it can balance its medical mission with digital initiatives. If Helius succeeds in implementing both directions, it may become an example of unique technological synergy that can transform not only the rehabilitation market but the entire model of digital healthcare.
Special attention should be paid to how the company manages its digital assets. The chosen strategy will affect not only financial stability but also the trust of the medical community. Helius’s success could inspire other companies to adopt blockchain tools in healthcare. Thus, the company’s future may be significant not only for investors but for the entire industry.
